Ian has over 43 years of pharmaceutical industry experience.

Prior to founding Juno/CPoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD.

Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics

Craig Podolsky is a founding partner at CPoint Capital and founder and president of the Juno Group of Companies (since 2012). Craig has over 18 years of experience seeding, investing and acquiring companies in the healthcare industry with a focus on generic and specialty pharmaceuticals and medical devices.

Prior to CPoint Capital and Juno he worked in various roles at Cobalt Pharmaceuticals. Craig earned his HBA from the Richard Ivey School of Business at the University of Western Ontario. He currently serves on the boards of Aspire Pharmaceuticals, Contura, Juno Pharmaceuticals Corp, and Conavi Medical.

Dr. Mandelzys has enjoyed more than 28 years in the biotech, specialty and generic pharmaceutical sector, with leadership roles spanning research and product development, business and corporate development and general management of both private and publicly traded companies.

Dr. Mandelzys joined CPoint Capital as a partner in 2022 and is also the Chief Operating and Development Officer for Juno Pharmaceuticals. He has been Chairman of Searchlight Pharmaceuticals since 2018 and a member of the Board of Matrizyme Pharma Corp., Exactis Innovation and Omega Laboratories, as well as a Board observer at numerous private entities. He is a former Board member of Clementia Pharmaceuticals up until its acquisition by Ipsen in 2019 and of Bedrocan Cannabis Corporation up until its amalgamation into Canopy Growth Corporation in 2015.

Prior to joining Juno in 2022, Dr. Mandelzys served as a strategic business and scientific consultant to the biotech industry, often assuming interim leadership positions within organizations. Prior to his consulting roles, Dr. Mandelzys served as CEO and director at Thallion Pharmaceuticals up until its acquisition by Bellus Health in 2013. Dr. Mandelzys served as vice president of business development at Labopharm from 2000 to 2006 through its IPO listing on the NASDAQ and held senior research and business development roles with Allelix Biopharmaceuticals from 1995 to 2000 through its acquisition by NPS Pharmaceuticals.

Dr. Mandelzys earned a PhD in physiology and an MBA from McGill University, and holds a BSc from the University of Toronto. He received his post-doctoral training at the Roche Institute of Molecular Biology.

Chris has more than 17 years of healthcare and pharmaceutical industry experience. Prior to CPoint he worked in progressive roles with Cobalt/Watson/Actavis Pharma which culminated as the Canadian Finance Country Head with Actavis Pharma and was a member of the leadership team managing cross-functional initiatives in a complex and results oriented environment.

During that time he gained experience in mergers and acquisitions and post acquisitions integration including in-depth support on $1.8 billion of transactions. Chris earned his CPA/CA while at KPMG.